# Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women

> **NCT03282799** · PHASE2 · COMPLETED · sponsor: **Catherine Anne Chappell** · enrollment: 72 (actual)

## Conditions studied

- HIV/AIDS
- Contraception

## Interventions

- **DRUG:** etonogestrel implant

## Key facts

- **NCT ID:** NCT03282799
- **Lead sponsor:** Catherine Anne Chappell
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-19
- **Primary completion:** 2020-12-22
- **Final completion:** 2022-10-25
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-09-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03282799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03282799, "Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03282799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*